Tag:
Alzheimer's
Latest Headlines
Latest Headlines
UC San Diego accuses USC of conspiring to grab Alzheimer's research, funding
Universities regularly woo top scientists from rival institutions, recruiting not only high-profile individuals but their lab teams as well in the hope of bagging promising science and the millions in federal funding that go along with it. But in a rare confrontation, UC San Diego has sued USC and research scientist Paul Aisen for an alleged conspiracy to purloin data and investigators involved in prominent Alzheimer's research work.
Roche forced to concede another flop for Alzheimer's program
You can score another setback for Roche's star-crossed attempt to develop a new drug for Alzheimer's. Roche partner Evotec reported that their drug sembragiline failed a Phase IIB study.
Researchers highlight a nuanced approach to flagging early Alzheimer's
Alzheimer's has long been one of the most contentious fields in drug development. As one drug after the next failed in late-stage clinical studies, drug developers have been moving further and further upstream in the disease process to see if they can more effectively blunt the progress of this disease in early-stage patients.
Alzheimer's biotech eyes $300M in a scaled-up IPO
Axovant Sciences, heading toward Phase III with an ex-GlaxoSmithKline treatment for Alzheimer's disease, has upped its IPO hopes to more than $300 million, betting it can win FDA approval where many others have failed.
Financier looks to parlay a $5M Alzheimer's deal into instant $172.5M IPO
Late last year, a newly formed Bermuda-based biotech struck a deal to in-license a shelved Alzheimer's drug from GlaxoSmithKline with plans to put it into Phase III. That late-stage study won't start until the fourth quarter, but the newborn biotech, now operating as Axovant Sciences, has filed for a $172.5 million IPO, looking to cash in fast on the still-sizzling market for biotech stocks.
Biogen gives Roche 'renewed confidence' in its own failed Alzheimer's drugs
Biogen turned heads around the industry last month with early data in which its plaque-destroying Alzheimer's treatment had a significant effect on patients' cognition, bucking a vexing trend for such antibodies. Among those paying close attention was Roche, which is now re-examining a pair of once-failed treatments.
Yale team says failed AstraZeneca drug shows promise in Alzheimer's
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
Yale team says failed AstraZeneca drug shows promise in Alzheimer's
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
Mayo Clinic team renews Alzheimer's feud, fingers tau over amyloid
In the world of Alzheimer's drug research, there's no lack of certainty among leading researchers. There's just no consensus on what causes the disease or how to treat it.
Queensland scientists use ultrasound to clear amyloid in Alzheimer's model
Up until now, most of the work focused on the amyloid beta theory on Alzheimer's has concentrated on drugs that can clear the toxic protein clusters many believe trigger brain damage and memory loss. But a team in Australia has been winning headlines around the world after demonstrating in mice that they can do the same thing with an ultrasound approach.
